Research programme: histone deacetylase inhibitors - Merck & Co.
Latest Information Update: 29 Aug 2011
$50 / €47 *
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for HIV infections in USA (unspecified route)
- 13 Mar 2007 Preclinical trials in HIV infections in USA (unspecified route)